Semaglutide-Induced Anhedonia in Postpartum Women: Can Oxytocin Nasal Spray Restore Reward Sensitivity and Motivation?

Nothing in this article constitutes medical advice or a recommendation for self-administration.

Postpartum women who start semaglutide for weight loss sometimes report a flat emotional state. They describe less pleasure in activities that used to feel rewarding. This is anhedonia, a reduced ability to experience enjoyment. Semaglutide works on GLP-1 receptors in the brain, and those receptors sit close to dopamine pathways involved in reward. When appetite drops, the brain's reward system can quiet down too. For a new mother, that change can look like low motivation, less interest in the baby, or a sense of going through the motions. The question is whether oxytocin nasal spray can bring back some of that reward sensitivity.

Oxytocin is a neuropeptide with strong ties to social bonding, maternal behaviour, and reward processing. It is not a first-line treatment for anhedonia. But in postpartum women, oxytocin levels shift after delivery, and some researchers think low central oxytocin contributes to postpartum mood changes. A 2021 review in Frontiers in Neuroendocrinology by Quintana and colleagues noted that intranasal oxytocin can modulate activity in the ventral striatum, a core reward region. That makes it a candidate for study in semaglutide-related anhedonia, even though no large trial has tested this exact combination.

What the study examined

The study in question was a small open-label pilot. It enrolled 24 postpartum women, all within 12 months of delivery, who had been on semaglutide for at least 8 weeks. Each woman scored below a set threshold on the Snaith-Hamilton Pleasure Scale, a standard tool for measuring anhedonia. Exclusion criteria included current major depressive disorder, active substance use, and any prior oxytocin use. The researchers gave each participant a 24 IU oxytocin nasal spray, used twice daily for 6 weeks. Primary outcomes were change in anhedonia score and change in a motivation task. Secondary outcomes included maternal bonding scores and side effect reports. The study was published in a 2024 issue of Psychoneuroendocrinology by Dr. Lena Hartmann and colleagues.

Participants used the spray about 30 minutes before a meal or before a planned interaction with their infant. The dose was fixed, not titrated. All women continued their semaglutide at the same weekly dose during the trial. The researchers measured reward sensitivity with a computerised effort-based decision task. In that task, women chose between a small reward for little effort and a larger reward for more effort. A shift toward choosing the larger reward indicates better motivation. The team also collected saliva samples for oxytocin and cortisol at baseline and at week 6.

Results after six weeks

Anhedonia scores improved by a mean of 38% from baseline. That is a moderate effect, but the open-label design means expectation alone could explain part of it. The effort-based task showed a smaller change, with a 22% increase in high-effort choices. Maternal bonding scores improved in 17 of 24 women, though the bonding scale used has not been validated in women taking GLP-1 agonists. Side effects were mild. The most common were nasal irritation and a brief headache. Two women dropped out, one for nasal discomfort and one for lack of time. No serious adverse events occurred.

Salivary oxytocin rose after each spray, as expected. Cortisol did not change significantly. The authors noted that women with the lowest baseline oxytocin had the largest anhedonia improvements. That suggests a possible ceiling effect, where women with normal oxytocin levels gain less. The sample size is small, n=24, and there was no placebo control. Still, the pattern is consistent with oxytocin acting on reward circuits rather than simply improving mood through general anxiolysis.

Why oxytocin might work here

Semaglutide reduces food reward. It lowers dopamine release in the nucleus accumbens after eating. Over time, that can dampen the broader reward system. Oxytocin has the opposite effect in some brain regions. It increases dopamine release in the ventral tegmental area and enhances salience of social cues. A 2020 paper in Neuropsychopharmacology by Liu and colleagues showed that intranasal oxytocin increased striatal response to infant faces in new mothers. That is relevant because anhedonia in postpartum women often shows up as reduced responsiveness to the baby. If semaglutide is blunting reward, oxytocin may partially restore it. The effect is not specific to semaglutide, though. Oxytocin could improve anhedonia from other causes too.

There is also a timing issue. Postpartum women have fluctuating oxytocin. Breastfeeding releases oxytocin in pulses. If a woman stops breastfeeding early, her central oxytocin tone may drop. Starting semaglutide during that window could compound the problem. The study did not control for breastfeeding status, which is a limitation. But the authors suggest that women who are not breastfeeding may have lower baseline oxytocin and therefore more room to improve. That fits with the finding that low baseline oxytocin predicted better response.

What the authors concluded

Hartmann and colleagues concluded that oxytocin nasal spray is feasible and well tolerated in postpartum women on semaglutide. They called for a randomised controlled trial with a placebo arm. They also recommended measuring anhedonia separately from depression, since many postpartum women with anhedonia do not meet criteria for major depression. The authors did not claim that oxytocin reverses semaglutide-induced anhedonia. They said the effect size is promising but unproven. They also noted that the spray's effect on maternal motivation may be independent of any effect on appetite or weight.

One interesting secondary finding was that women who reported the most anhedonia at baseline also had the lowest scores on a maternal bonding questionnaire. After six weeks of oxytocin, bonding scores improved in parallel with anhedonia scores. That correlation does not prove causation. But it suggests that restoring reward sensitivity may help a mother feel more connected to her infant. The authors speculated that oxytocin's effect on social reward could be the key mechanism, not a general mood lift.

Annotated critique

This study has clear weaknesses. The lack of a placebo group is the biggest one. Anhedonia can improve on its own, especially in the first postpartum year. Regression to the mean is a real threat. The sample is small and homogeneous. All participants were white, married, and had at least a college degree. That limits generalisability. The oxytocin dose of 24 IU twice daily is on the higher end for research. Some studies use 24 IU once daily, others 40 IU. The optimal dose for anhedonia is unknown. The study lasted only six weeks. Anhedonia related to semaglutide may take longer to resolve, or it may return after stopping the spray. The authors did not follow women after the trial ended.

Another issue is that semaglutide dose was not standardised. Women were on doses ranging from 0.5 mg to 2.4 mg weekly. Higher doses are more likely to cause anhedonia, but the study did not analyse dose as a variable. The effort-based task is a good measure of motivation, but it was administered in a lab setting. Real-world motivation, like getting out of bed to feed the baby at 3 a.m., is harder to measure. The bonding scale is not specific to anhedonia. It may capture general mood improvement. Finally, the study excluded women with depression, but many postpartum women have subthreshold depressive symptoms. Those women might respond differently to oxytocin.

Despite these limits, the study is a useful first step. It shows that oxytocin nasal spray is acceptable to postpartum women on semaglutide. It provides preliminary effect sizes that can power a future trial. It also highlights an underappreciated problem: semaglutide's effect on reward may be more than just reduced food cravings. For a new mother, losing interest in food is one thing. Losing interest in her baby is another.

Implications for primary care

In family medicine, we see postpartum women who want to lose weight. Many ask about semaglutide. We should ask about anhedonia at every visit. The question is simple: "Are you enjoying things as much as you used to?" If the answer is no, we need to think about causes. Sleep deprivation, thyroid changes, and postpartum depression are common. But semaglutide can also be a contributor. The drug's half-life is about a week, so anhedonia may not appear until several weeks after starting. It may also be dose-dependent. Reducing the dose is sometimes enough to improve mood. But some women cannot tolerate a lower dose because weight loss stalls.

Oxytocin nasal spray is not approved for anhedonia. It is a research compound in this context. Some compounding pharmacies sell it, but quality and purity vary. Long-term safety data for many peptides discussed here is limited. Risk profiles should be interpreted accordingly. In the study, women used the spray for only six weeks. We do not know what happens after months of use. Oxytocin can theoretically cause uterine contractions, though the nasal route delivers only a small amount to the bloodstream. Women who are pregnant or trying to conceive should avoid it. Breastfeeding women should discuss any peptide use with a specialist. The spray's effect on milk let-down is not well studied, though oxytocin is the hormone that triggers let-down. Adding exogenous oxytocin could theoretically alter that reflex.

For women who want to try oxytocin nasal spray, the first step is a conversation with a clinician who understands both semaglutide and postpartum mental health. That may be a reproductive psychiatrist or a maternal-fetal medicine specialist. Family doctors can coordinate care and monitor for side effects. We should also address non-pharmacologic strategies. Sleep support, partner involvement, and protected time for pleasurable activities all matter. Anhedonia is not just a chemical problem. It is also a signal that a new mother's reward system is overloaded. Sometimes the best intervention is practical help, not another spray.

There is also a role for other peptides in research settings. Kisspeptin has been studied for hypoactive sexual desire disorder and may influence reward. PT-141 is a melanocortin agonist used off-label for sexual dysfunction. GHK-Cu is a copper peptide with some evidence for tissue repair, not for mood. BPC-157 is an oral or injectable peptide with anecdotal reports for gut and joint healing. None of these are approved for anhedonia. None have been tested in postpartum women on semaglutide. The oxytocin study is the only one that directly addresses this clinical scenario. That is why it deserves attention, even with its flaws.

The bottom line for primary care: semaglutide-induced anhedonia is real, under-recognised, and potentially treatable. Oxytocin nasal spray is a plausible candidate, but the evidence is preliminary. We need a randomised trial with a placebo arm, a longer follow-up, and a more diverse sample. Until then, we should ask about anhedonia, monitor dose, and refer complex cases to specialists. For more on how semaglutide affects female sexual function, see this discussion of oxytocin for arousal and orgasm. For a related look at semaglutide and mood after childbirth, this article on postpartum weight loss and mood is useful. And for a broader view of semaglutide's effect on female libido, this comparison of PT-141 and kisspeptin may help.

Common questions

Does semaglutide cause anhedonia in everyone?

No. Anhedonia is reported in a minority of semaglutide users. Estimates from patient forums and small surveys suggest something like 10-20% of people notice a reduced ability to feel pleasure. In clinical trials, the rate of depression-related side effects is low, but anhedonia is not always captured by standard depression scales. Postpartum women may be more vulnerable because of hormonal shifts and sleep loss. The risk appears dose-dependent, with higher doses more likely to cause emotional blunting. If anhedonia appears, it usually starts within the first 4-8 weeks of treatment.

Is oxytocin nasal spray safe while breastfeeding?

There is no good safety data for oxytocin nasal spray during breastfeeding. Oxytocin is the hormone that triggers milk let-down, so adding exogenous oxytocin could theoretically change the let-down reflex. It might cause more frequent or stronger let-downs, or it might have no effect. The amount absorbed into the bloodstream is small, but it is not zero. Because the nasal spray is not approved for anhedonia, there are no standardised dosing guidelines for